What does Novo Nordisk Production Belgium SA do?

Novo Nordisk Production Belgium SA is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 22 April 1999, 1 establishment.

What is the address of Novo Nordisk Production Belgium SA?

The registered office of Novo Nordisk Production Belgium SA is located at Sint Lendriksborre 10, 1120 Brussel.

Is Novo Nordisk Production Belgium SA still active?

Yes. According to the CBE (15 November 2026) Novo Nordisk Production Belgium SA is active, legal situation “Normale toestand”, started on 22 April 1999.

Is Novo Nordisk Production Belgium SA registered on Peppol?

Yes, Novo Nordisk Production Belgium SA is registered on the Peppol network with ID 0208:0465935738.

What is the enterprise number of Novo Nordisk Production Belgium SA?

The enterprise number of Novo Nordisk Production Belgium SA is BE0465935738.

When was Novo Nordisk Production Belgium SA founded?

Novo Nordisk Production Belgium SA was founded on 22 April 1999.

Who are the directors of Novo Nordisk Production Belgium SA?

According to the 2025 annual accounts, the directors of Novo Nordisk Production Belgium SA are: Ramon CERON, John KUCKELMAN, Erik, Lorin RASMUSSEN, Andrew FINNEGAN, Geoffroy BECKERS, Sabine CARLINO, Bruno STUTZMANN, Dzenana CENGIC.

Is Novo Nordisk Production Belgium SA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 April 1999; 4 annual accounts filed, latest fiscal year 2025; 8 directors known from the annual account.

How much profit did Novo Nordisk Production Belgium SA make in 2025?

Novo Nordisk Production Belgium SA posted a profit after taxes of € 11,871,593 in financial year 2025.

What is the revenue of Novo Nordisk Production Belgium SA?

In its most recent annual accounts (2025), Novo Nordisk Production Belgium SA reported revenue of € 258,618,660.

How much does an employee at Novo Nordisk Production Belgium SA earn?

The average wage cost per full-time employee at Novo Nordisk Production Belgium SA was € 158,200 in 2025: staff costs of € 92.9 million for 587.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Novo Nordisk Production Belgium SA have?

According to the 2025 annual accounts, Novo Nordisk Production Belgium SA has 587.2 full-time equivalents (FTE).

Novo Nordisk Production Belgium SA (Public Limited)

Dossier Novo Nordisk Production Belgium SA, printed on 15 November 2026 from databakkes.be/en/0465935738/novo-nordisk-production-belgium-sa. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2025.

Financials

Financial year 2025

Novo Nordisk Production Belgium SA from Brussel, company number BE0465935738, closed financial year 2025 with a result of € 11.9 million after tax. For that financial year Novo Nordisk Production Belgium SA recorded revenue of € 258.6 million and equity of € 74.2 million. Compared with financial year 2024, the result moved from € -7.5 million to € 11.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Growing

€ 74.2 million

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 11.9 million

▲ still € 7.5 million loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 6.5 million

▼ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -42.8 million.

People and assets in 2025

Full-time equivalents

587.2

▲ 29 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 92.9 million

▲ 84% vs 2024

€ 158,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1 million

▼ 18% vs 2024

Of which on lease € 800,000.

Debts at end 2025

Bank debt ≈ 17 years to go

€ 4.8 million

▼ 72% vs 2024

€ 80,000 is repaid this year. At this pace the long-term loan is gone in ≈ 17 years.

Owed to suppliers

€ 43.8 million

▲ 65% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 104 days on average.

Taxes and wages

€ 16.9 million

▲ 91% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 52,256,616 Revenue 2022: € 52,256,616 First fiscal year in the series	€ 57,028,590 Revenue 2023: € 57,028,590 ▲ 9% vs 2022 (€ 52,256,616) Favourable step	€ 134,557,529 Revenue 2024: € 134,557,529 ▲ 136% vs 2023 (€ 57,028,590) Favourable step	€ 258,618,660 Revenue 2025: € 258,618,660 ▲ 92% vs 2024 (€ 134,557,529) Favourable step	▲ 92%
Profit after taxes	€ -46,690,437 Profit after taxes 2022: € -46,690,437 First fiscal year in the series	€ 5,629,164 Profit after taxes 2023: € 5,629,164 ▲ € 52.3 million vs 2022 (€ -46,690,437) Favourable step	€ -7,517,040 Profit after taxes 2024: € -7,517,040 ▼ € 13.1 million vs 2023 (€ 5,629,164) Unfavourable step	€ 11,871,593 Profit after taxes 2025: € 11,871,593 ▲ € 19.4 million vs 2024 (€ -7,517,040) Favourable step	▲ € 19.4 million
Equity	€ 64,241,204 Equity 2022: € 64,241,204 First fiscal year in the series	€ 69,870,368 Equity 2023: € 69,870,368 ▲ 9% vs 2022 (€ 64,241,204) Favourable step	€ 62,353,328 Equity 2024: € 62,353,328 ▼ 11% vs 2023 (€ 69,870,368) Unfavourable step	€ 74,224,921 Equity 2025: € 74,224,921 ▲ 19% vs 2024 (€ 62,353,328) Favourable step	▲ 19%
Total debts	€ 74,597,172 Total debts 2022: € 74,597,172 First fiscal year in the series	€ 45,470,921 Total debts 2023: € 45,470,921 ▼ 39% vs 2022 (€ 74,597,172) Favourable step	€ 75,871,188 Total debts 2024: € 75,871,188 ▲ 67% vs 2023 (€ 45,470,921) Unfavourable step	€ 72,442,045 Total debts 2025: € 72,442,045 ▼ 5% vs 2024 (€ 75,871,188) Favourable step	▼ 5%
Cash	€ 42,267,496 Cash 2022: € 42,267,496 First fiscal year in the series	€ 1,333,437 Cash 2023: € 1,333,437 ▼ 97% vs 2022 (€ 42,267,496) Unfavourable step	€ 6,857,256 Cash 2024: € 6,857,256 ▲ € 5.5 million vs 2023 (€ 1,333,437) Favourable step	€ 6,495,193 Cash 2025: € 6,495,193 ▼ 5% vs 2024 (€ 6,857,256) Unfavourable step	▼ 5%
Land & buildings	€ 15,488,178 Land & buildings 2022: € 15,488,178 First fiscal year in the series	€ 21,870,077 Land & buildings 2023: € 21,870,077 ▲ 41% vs 2022 (€ 15,488,178) Unchanged	€ 20,519,810 Land & buildings 2024: € 20,519,810 ▼ 6% vs 2023 (€ 21,870,077) Unchanged	€ 21,969,694 Land & buildings 2025: € 21,969,694 ▲ 7% vs 2024 (€ 20,519,810) Unchanged	▲ 7%
Retained profit	€ -52,794,920 Retained profit 2022: € -52,794,920 First fiscal year in the series	€ -47,165,756 Retained profit 2023: € -47,165,756 ▲ € 5.6 million vs 2022 (€ -52,794,920) Favourable step	€ -54,682,795 Retained profit 2024: € -54,682,795 ▼ € 7.5 million vs 2023 (€ -47,165,756) Unfavourable step	€ -42,811,202 Retained profit 2025: € -42,811,202 ▲ € 11.9 million vs 2024 (€ -54,682,795) Favourable step	▲ € 11.9 million
Bank debt	€ 36,694,072 Bank debt 2022: € 36,694,072 First fiscal year in the series	€ 7,529,028 Bank debt 2023: € 7,529,028 ▼ 79% vs 2022 (€ 36,694,072) Favourable step	€ 16,870,317 Bank debt 2024: € 16,870,317 ▲ 124% vs 2023 (€ 7,529,028) Unfavourable step	€ 4,797,665 Bank debt 2025: € 4,797,665 ▼ 72% vs 2024 (€ 16,870,317) Favourable step	▼ 72%
Balance sheet total	€ 138,838,375 Balance sheet total 2022: € 138,838,375 First fiscal year in the series	€ 115,341,289 Balance sheet total 2023: € 115,341,289 ▼ 17% vs 2022 (€ 138,838,375) Unchanged	€ 138,224,517 Balance sheet total 2024: € 138,224,517 ▲ 20% vs 2023 (€ 115,341,289) Unchanged	€ 153,475,766 Balance sheet total 2025: € 153,475,766 ▲ 11% vs 2024 (€ 138,224,517) Unchanged	▲ 11%
Employees (FTE)	515.6 Employees (FTE) 2022: 515.6 First fiscal year in the series	540.6 Employees (FTE) 2023: 540.6 ▲ 25 vs 2022 (515.6) Unchanged	558.2 Employees (FTE) 2024: 558.2 ▲ 17.6 vs 2023 (540.6) Unchanged	587.2 Employees (FTE) 2025: 587.2 ▲ 29 vs 2024 (558.2) Unchanged	▲ 29

By revenue, Novo Nordisk Production Belgium SA ranks 5th of 15 companies with main activity “Vervaardiging van geneesmiddelen” in the Brussels Region that publish figures (fiscal year 2025).

Key figures of Novo Nordisk Production Belgium SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

Ask about Novo Nordisk Production Belgium SA the way you would ask their accountant.

Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.

Connect ChatGPT or Claude for free

ChatGPT
Claude

Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.

What happened to Novo Nordisk Production Belgium SA?

What happened at Novo Nordisk Production Belgium SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 John KUCKELMAN stepped down as director. NBB
2031 Erik, Lorin RASMUSSEN stepped down as director. NBB
2031 Andrew FINNEGAN stepped down as director. NBB
2031 Geoffroy BECKERS stepped down as director. NBB
2031 Sabine CARLINO stepped down as director. NBB
2031 Dzenana CENGIC stepped down as director. NBB
Jul 31, 2026 Corrected annual accounts filed for financial year 2025. Source: NBB ↗
2025 Bruno STUTZMANN stepped down as director. NBB

In short

From € 46.7 million loss in 2022 to € 11.9 million profit in 2025.

Paid € 1.8 million in corporate taxes since 2022.

Best year ever: 2025, with € 11.9 million profit.

Pays suppliers within 104 days on average.

Original PDFs at the National Bank ↗

Management

Novo Nordisk Belgium Manufacturing Holding S 100%

Novo Nordisk Production Belgium SA

The shares are held by Novo Nordisk Belgium Manufacturing Holding S (100%).

Directors

According to the 2025 annual accounts

Ramon CERON

Director

Also active at: CATALENT BELGIUM HOLDING

since 2024 · until 2024

John KUCKELMAN

Director

Also active at: Novo Nordisk Belgium Manufacturing Holding SA

since 2024 · until 2031

Erik, Lorin RASMUSSEN

Director

Also active at: Novo Nordisk Belgium Manufacturing Holding SA

since 2024 · until 2031

Andrew FINNEGAN

Director

Also active at: Novo Nordisk Belgium Manufacturing Holding SA

since 2024 · until 2031

Geoffroy BECKERS

Managing director

Also active at: Novo Nordisk Belgium Manufacturing Holding SA, AM Biologics Filling Brussels

since 2025 · until 2031

Sabine CARLINO

Director

Also active at: Novo Nordisk Belgium Manufacturing Holding SA

since 2025 · until 2031

Bruno STUTZMANN

Managing director

Also active at: CATALENT BELGIUM HOLDING

since 2024 · until 2025

Dzenana CENGIC

Managing director

since 2025 · until 2031

Shareholders

Novo Nordisk Belgium Manufacturing Holding S

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Sint Lendriksborre 10

1120 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Novo Nordisk Belgium Manufacturing Holding SA same network

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Similar companies in the Brussels Region

Same main activity (Vervaardiging van geneesmiddelen), 21 active companies in the Brussels Region, largest first.

UCB PHARMA

€ 4.6 billion revenue · 2025 · Anderlecht

UCB BIOPHARMA

€ 3.6 billion revenue · 2025 · Anderlecht

PHOENIX Pharma Belgium

€ 1.1 billion revenue · 2023 · Sint-Lambrechts-Woluwe

ROCHE

€ 448.8 million revenue · 2025 · Anderlecht

LABORATOIRES S.M.B.

€ 112.5 million revenue · 2025 · Sint-Jans-Molenbeek

Ipsen

€ 71.3 million revenue · 2025 · Brussel

All companies with this activity → Largest companies in Brussel →

Details

Company number

0465.935.738

VAT number

BE 0465.935.738

Registered office

Sint Lendriksborre 10, 1120 Brussel

Names & denominations

Novo Nordisk Production Belgium SA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

22 April 1999

Peppol

Active · Active since 3 Oct 2025

Activities · NACE

Vervaardiging van geneesmiddelen

Vervaardiging van overige farmaceutische producten

Vervaardiging van overige farmaceutische preparaten

View on CBE Public ↗ Annual accounts (NBB) ↗

Novo Nordisk Production Belgium SA

Warning lights

Financials

Ask about Novo Nordisk Production Belgium SA the way you would ask their accountant.

What happened to Novo Nordisk Production Belgium SA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Similar companies in the Brussels Region

Details

Frequently asked questions